Michael Burry (Trades, Portfolio), of Big Short fame, has made some waves for calling out AI companies, alleging that they are understating depreciation by extending the useful life of assets artificially boosts earnings. In case you’re unfamiliar, Burry was one of the first to spot the housing crisis that set off the Great Recession. I have a lot of respect for Mr. Burry, so I wouldn’t write his comments off. That said, there are some important caveats worth discussing.
Separately, I’ve been lightly researching AI chip obsolescence because it’s been a popular topic on Reddit and other places. Burry’s comments immediately piqued my attention. A common argument is that AI chips become obsolete after just a few years because newer chips offer stronger computing power and/or energy efficiency. This specific argument, I believe, is misplaced because older AI chips will still have many relevant uses running older and/or lighter AI models rather than the bleeding-edge models. These lighter models represent a hot potential growth area, making older chips not just viable but valuable. I can’t say for certain that Burry is worried about obsolescence, but he has mentioned useful lifespan.
Another concern: How long will the chips last before physically breaking down? I have not found a conclusive answer, but so far, my impression is that they typically last longer than 3 years. If the lifespan average falls under three years, Burry’s argument gains a lot of strength. If the chips can last significantly longer, however, that’d create headwinds for his thesis.
So far, Burry has been rather vague concerning the matter, so it’s hard (impossible?) to evaluate his argument. Details are forthcoming, but for now, we can consider possible angles and perhaps more importantly, critique common arguments and popular beliefs. With that in mind, I believe it’s important to take a deeper look at the potential lifecycle for AI chips. Until I see Burry’s argument, I can’t really refute it, but I believe the discussion below is important, and if nothing else, will provide readers with useful food for thought. It should also act as a primer for when Burry makes his November 25th release.
Michael Burry Stirs Up Chip Depreciation Controversy: Important Context To Consider
All of this is important for investors owing to concerns over the AI race and potential bubble. Stock markets and the economy have, in many ways, been propped up by AI investments. Valuations have been pushed high with AI companies leading the charge. Outside of AI investments, the American economy seems to be teetering on the verge of recession. If Burry is correct, it’ll inject a lot of skepticism into the markets, potentially causing corrections. It could also call into question the viability of current strategies and use cases around AI.
Twenty years ago, basic home computers often started to become quite sluggish (and perhaps short on storage) within just a few years. Upgrades were common as chips advanced at a rapid pace and the advances greatly improved the home computing experience. Often, obsolescence happened quicker for laptops rather than desktops, but still, useful lifecycles could be quite short. These days, it’s pretty common to see people hold onto laptops for substantially longer because the computer still meets their needs.
I mention this anecdotal experience simply to illustrate that hardware can remain quite useful past optimal lifespans. Bleeding-edge chips will lose their bleeding-edge much more quickly, but that doesn’t mean they’re useless even when pulled from the frontier. On a roughly annual basis, new gaming GPUs come out that offer better performance than the last model, and if you want the best graphics, you’ll need to upgrade pretty quickly. The same will prove true for data center chips: the next generation will typically perform substantially better.
For developers working on bleeding-edge frontier AI models, even seemingly minor boosts in performance, energy efficiency, and other metrics can make a big difference. Those developers working on the biggest and most cutting-edge AI models will probably move to upgrade as quickly as possible. The race to develop AI right now is white hot, with multiple massive competitors pouring vast resources into development. With so much poured in and the potential upside so high, quick upgrades are not just viable but logical.
Yet while a lot of public attention and media emphasis is on bleeding-edge frontier models, lighter (and older) models still remain relevant for a variety of tasks, and when it comes to leveraging AI for use in daily life, these lighter models can be just as effective, if not more so, than the bleeding-edge models. For example, many AI models can be run on a scaled-down model version locally. This is useful for smaller developers, and also businesses that, for security needs or otherwise, want to keep their data locally hosted and perhaps completely offline.
Many AI tools, including chatbots and various agents, simply don’t need all of the power of the frontier models. Cost concerns with frontier AI models, including how expensive they are to run, are prominent. The most advanced models consume the most energy and need the most chips, making them especially expensive to run. Some sources report that a six-month training run with GPT-5 costs $500 million. To be clear, training runs are especially intensive, but the point is: running the latest models is very expensive.
Michael Burry Stirs Up Chip Depreciation Controversy: Important Context To Consider
If you look at GPT-5’s pricing (shown above), on the surface, it actually looks substantially cheaper than GPT-4 (shown below). My initial thought was that OpenAI was simply trying to encourage people to use the latest model and thus set up their price structure to encourage that. However, a very insightful post by Zack Saadioui, which I recommend you check out, offers some crucial insights. The short of it is, when you use GPT-5, the request is sent to a central router, which from there, decides which model to use based on the difficulty of your request. As shown below, there are a variety of GPT-5 models of increasing sophistication, and the lightest models are much cheaper.
Michael Burry Stirs Up Chip Depreciation Controversy: Important Context To Consider
Further, GPT-5 uses so-called reasoning tokens. These tokens basically align with the internal thought process of the model, and the more thought processes you use to process your request, the more tokens you use. Further, these tokens are counted as output tokens, which are more expensive than input. Long’ish story short: the more complex your request, the more it’s going to cost. If you need the most fully powered model and thus compute power, you’re going to pay quite a bit more. If your request is relatively simple, it’ll be directed to the lighter-weight, cheaper GPT-5 models.
Going forward, I believe we’ll see this broken down at the hardware level with the most advanced models processing the most complex requests using the most reasoning tokens to run the most cutting-edge hardware. Yet ChatGPT (and other providers) should be able to use older hardware to run lighter nano models to process simpler requests. We talk about planned obsolescence with consumer goods, but for AI companies, we’re more likely to see planned downscaling with lighter and older models simply using older chips.
Another point worth mentioning, by the way, is that Chinese developers have made major breakthroughs on limited hardware, showing how lighter models and slower GPUs can be used to produce results. I suspect the current efforts of developers in China show (at least in part) the future of older GPUs being taken off frontier development.
My general thesis that chips have a substantially longer lifespan than 3 years could quickly be disproven if we find out that chips are failing at a high rate after just a few years. The chips might have remained useful if they were still functioning, but a burned-out chip is probably little more than recycling material at this point. This is a question I’ve been trying to answer definitively with light research over the past few weeks. So far, I’m finding mixed messages.
This study found that the last time a specific AI chip is used to train a frontier model (bleeding edge) is about 2.7 years. But I’m not as concerned about frontier models as outlined above. A commenter on this forum notes that general data center chips last 4 to 6 years (I’ve seen this mentioned elsewhere for standard data centers), but suspects that AI chips will last longer. That said, a Google employee has claimed that with high utilization, chips may last only 1 to 3 years, but potentially up to 5 with more moderate use. If this is true, Burry’s worries about short lifespans may be accurate even outside of useful lifespans.
CoreWeave, so far, may offer the most conclusive evidence. In a study with a 1024 GPU cluster in operation, the Mean Time to Failure was 3.66 days, which as I understand, means that when running a cluster, the first GPU will burn out after 3.66 days. This means that over the course of a year, about 100 GPUs will burn out. Thus at a constant rate, by year three, around a third of GPUs will have burned out. This number is pretty high, but it should also be noted that researchers are finding ways to extend chip life and mitigate physical damage. Further, it’s unlikely that any cluster will actually run 24/7 365 days a year.
There is one last point I want to quickly touch on. Newer chips may prove more energy efficient than previous chips, thus lowering operating costs. At some point, the calculus could shift to newer chips being cheaper overall due to energy savings. However, computing power rather than energy efficiency seems to be the chief concern, for now, since major players are racing to build the most powerful models. Energy, while limited, simply isn’t as crucial a concern at the moment as compute is. Further, demand for compute is so high that it would likely take many years for more energy-efficient chips to satisfy demand overall, which means older chips will likely remain in use.
We’ll find out more on November 25th when Burry releases more details. I suspect there will be a lot of buzz and likely industry leaders will push back rather quickly. Hopefully, they bring forward hard evidence, including the lifespan of their chips and how they justify the depreciation, financially speaking. Markets may suffer some turbulence, but even if there is an AI bubble, I’d be surprised if this were the pin to pop it. That said, if Burry’s argument is convincing, investors heavily exposed to AI should, at the very least, take time to evaluate their positions and risks.
The Leica M-A owned by the late pontiff is one of the most valuable models ever sold at auction.
Pope Francis’s Leica M-A film camera sold for more than $7M. (photo by Christoph Welkovits, all courtesy Leitz Photographica Auction)
Say formaggio!
A blindingly white-and-silver Leica camera owned by the late Pope Francis sold at a European auction this weekend for about $7.5 million, nearly 100 times its estimate.
It was one of the most expensive Leica models ever sold, according to Leitz Photographica Auction, which announced it would auction the Pope’s mechanical camera for charity in September. The record is still held by a 100-year-old prototype that sold for $16.7 million in 2022.
The camera company presented a personalized Leica M-A film camera and its Noctilus-M 50 mm lens to his holiness last year. In a statement, the auction house said Pope Francis had decided to auction the Leica and donate the proceeds “in keeping with his commitment to charity and social causes.”
The camera was gifted to the pontiff before he passed away last year.
The camera kit features several unique elements that distinguish it from its base model, which retails for about $6,300 for the body and another $8,500 for the lens, before taxes. It carries a distinctive serial number of 5000000, which is valuable to collectors, and its white-painted top plate includes an engraving with Pope Francis’s motto miserando atque eligendo (which translates to “by having mercy and choosing,” drawn from a homily on the call of Saint Matthew by Saint Bede the Venerable). The flash cover is engraved with the keys of Peter.
Both the body and lens caps are engraved with the Coat of Arms of the State of Vatican City, and the camera and lens include an etching that reads “AD MMXXIV,” the year Leica presented the Pope with the gift in Roman numerals.
The white-painted top plate is engraved with Pope Francis’s motto.
It’s unclear whether Pope Francis got to use his camera much, but he didn’t own it very long. He passed away this spring at the age of 88, several months after receiving the gift.
Though the pontiff did not specifically express his views on photography, he was a vocal supporter of art and artists. “Architects and painters, sculptors and musicians, filmmakers and writers, photographers and poets, artists of every discipline, are called to make beauty shine,” he said during a 2016 address to the Pontifical Academies, “especially where darkness and greyness dominate everyday life.”
In late November 2025, Goldman Sachs completed a series of fixed-income offerings totaling over US$120 million in senior and subordinated notes with varied maturities and fixed coupons, while also securing exclusive negotiation rights to purchase Restaurant Brands International’s Japan operations, valued at around ¥70 billion (US$452 million).
The combination of successful bond issuances and expansion opportunities reflect Goldman Sachs’ continued focus on strengthening its capital base and diversifying its business activities.
We’ll examine how Goldman Sachs’ strong performance in investment banking and recent capital market activities shape the company’s investment narrative.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
To be a shareholder in Goldman Sachs Group, you need to believe in the firm’s ability to drive long-term growth through its core strengths in investment banking, asset management, and capital markets innovation. The recent series of fixed-income offerings and the exclusive negotiation rights for Restaurant Brands International’s Japan operations highlight Goldman’s focus on capital strength and business diversification. These actions have no material impact on the company’s main short-term catalyst, which remains robust M&A activity, or on its largest current risk: regulatory uncertainty and pending changes to capital requirements.
Among recent announcements, the acquisition of exclusive rights to negotiate the purchase of RBI’s Japanese operations is particularly relevant. This move underscores Goldman’s pursuit of high-profile deals and international expansion, supporting its ongoing strategy of seeking new revenue streams beyond its traditional segments and reinforcing the investment banking backlog that continues to fuel advisory revenues.
But contrasting the company’s expansion efforts, investors should also be aware of upcoming regulatory challenges and potential increases in compliance costs, because…
Read the full narrative on Goldman Sachs Group (it’s free!)
Goldman Sachs Group’s outlook anticipates $61.4 billion in revenue and $17.0 billion in earnings by 2028. This is based on a projected annual revenue growth rate of 3.9% and a $2.3 billion increase in earnings from the current $14.7 billion.
Uncover how Goldman Sachs Group’s forecasts yield a $802.53 fair value, a 3% downside to its current price.
GS Community Fair Values as at Nov 2025
Nine private investors from the Simply Wall St Community set fair values for Goldman Sachs between US$498,314 and US$815,000, highlighting widely differing views. These contrasting opinions come as new regulatory risks could reshape the company’s future profitability, so consider several viewpoints before deciding.
Explore 9 other fair value estimates on Goldman Sachs Group – why the stock might be worth 40% less than the current price!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
A great starting point for your Goldman Sachs Group research is our analysis highlighting 5 key rewards that could impact your investment decision.
Our free Goldman Sachs Group research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Goldman Sachs Group’s overall financial health at a glance.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Wondering if Tokyo GasLtd is fairly priced, or if the market is missing something? You’re in the right place for a deeper dive into its true value.
Shares have been on a strong run lately, with an 18.9% jump over the past month and an impressive 44.4% rally so far this year. This hints at changing growth expectations and risk appetite.
Recent news has highlighted the company’s strategic investments in renewable energy and its push towards decarbonization. Both factors are helping drive renewed investor interest. These developments have provided fresh context for the stock’s upward momentum as Tokyo GasLtd adapts to evolving energy trends in Japan.
But does the current price reflect the fundamentals? Based on a valuation score of 2 out of 6, there is more to uncover. Not just by the numbers, but by exploring smarter ways to value stocks. Stay tuned for a practical walkthrough and a different approach later in the article.
Tokyo GasLtd scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
A Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future cash flows and discounting them back to today’s value. This approach provides a grounded sense of what the business is really worth, based on its ability to generate cash in the years ahead.
For Tokyo GasLtd, the most recent Free Cash Flow reported is approximately ¥146.3 billion. Analyst estimates predict some fluctuation over the next decade, with projected Free Cash Flow for the year ending March 2030 around ¥78.4 billion. It is important to note that while detailed analyst forecasts typically only reach five years, later projections are extrapolated based on recent trends.
According to the DCF model, this steady outlook leads to an estimated intrinsic value of ¥5,370 per share. Currently, the stock is trading at a level that is 17.9% above this calculated fair value. This suggests that Tokyo GasLtd is trading at a noticeable premium relative to its underlying cash flow generation potential.
Result: OVERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Tokyo GasLtd may be overvalued by 17.9%. Discover 913 undervalued stocks or create your own screener to find better value opportunities.
9531 Discounted Cash Flow as at Nov 2025
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Tokyo GasLtd.
The Price-to-Earnings (PE) ratio is a widely used valuation metric for profitable companies like Tokyo GasLtd because it ties a company’s share price directly to its current ability to generate profits. For investors, the PE ratio provides a clear picture of how much the market is willing to pay for each yen of earnings, making it a practical gauge for relative valuation.
Growth expectations and perceived risks play a big role in determining what is considered a “normal” or “fair” PE ratio. Companies expected to grow faster or those operating in lower-risk environments may justify higher PE multiples, while slower growth or higher risk can bring the ratio down below sector norms.
At present, Tokyo GasLtd is trading at a PE ratio of 11.6x. This is below both the industry average for Gas Utilities of 14.4x and the peer group average of 16.3x, suggesting the market is more cautious than the broader sector or Tokyo GasLtd’s direct competitors.
Simply Wall St’s proprietary “Fair Ratio” offers a more tailored benchmark, blending factors such as Tokyo GasLtd’s profit margins, growth profile, market cap, risk exposures, and its industry context. This customized ratio, 7.4x for Tokyo GasLtd, provides a deeper, company-specific gauge of value than standard industry averages or peer comparisons, which can miss nuance around a company’s individual prospects and risks.
Since the market PE ratio of 11.6x is notably higher than the Fair Ratio of 7.4x, Tokyo GasLtd appears overvalued by this measure, even though it seems less expensive than other peers and its industry on traditional multiples.
Result: OVERVALUED
TSE:9531 PE Ratio as at Nov 2025
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1437 companies where insiders are betting big on explosive growth.
Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is a simple, approachable way for investors to describe their perspective on a company like Tokyo GasLtd, providing the story behind their numbers by sharing assumptions about fair value, future revenue, earnings, and margins.
Narratives connect each investor’s story to a specific financial forecast, turning personal insights into a calculated fair value and actionable investment view.
Using Simply Wall St’s Community page, millions of investors can easily access, create, and compare Narratives, making it simple to see how different viewpoints influence when to buy or sell, especially by comparing each Narrative’s Fair Value to the current Price.
Narratives are dynamic and instantly update with new information such as news or earnings releases, so your valuation story is always current.
For example, among Tokyo GasLtd Narratives, some investors are optimistic and estimate a much higher future fair value based on strong growth in renewables, while others take a more cautious stance and see a much lower fair value.
Do you think there’s more to the story for Tokyo GasLtd? Head over to our Community to see what others are saying!
TSE:9531 Earnings & Revenue History as at Nov 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 9531.T.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Research and Real-world Outcomes Underscore Transpara Breast AI’s Impact on Cancer Detection and Breast Imaging Workflow
CHICAGO, Nov. 30, 2025 /PRNewswire/ — ScreenPoint Medical is showcasing the industry-leading Transpara Breast AI suite, an integrated set of solutions that includes Detection, Density, and Temporal Comparison at the 111th Annual Radiological Society of North America (RSNA) Annual Meeting, November 30-December 4, 2025 (South Hall #4719). The most clinically validated Breast AI on the market, Transpara Breast AI is built for enterprise workflows to provide radiologists with a ‘second pair’ of eyes to help detect cancer earlier, reduce radiologist workload, and improve program performance.
2025 has been a pivotal year for ScreenPoint Medical. Surpassing 11 million mammograms processed, Transpara Breast AI is deployed in over 30 countries at leading healthcare providers and has been selected by 40% of the 2025 US News and World Report’s Top 20 Best Hospitals Honor Roll recipients.
Additionally, Transpara Breast AI has been chosen in to be part of the only randomized controlled trials (RCTs) in the field of Breast AI: the MASAI RCT in Sweden and the upcoming $16mil PRISM RCT in the United States, which will commence in early 2026 and is spearheaded by researchers at UCLA and UC Davis. Results from MASAI published earlier this year found a 29% increase in cancer detection and a 44% decrease in screen-reading workload when using Transpara Detection compared to the standard of care.
Risk assessment is also a key theme at RSNA 2025: Transpara Risk, an image-based 5-year risk model for breast cancer, and Transpara Detection are the subjects of a powerful new study, “Added Value of Breast Cancer Risk Prediction Versus Detection Over a Two-year Time Period with Mammography” (S5-SSBR02-4, Sunday, November 30, 2:30 PM, S406A). This research shows the added value of risk prediction for precision care, with Transpara solutions outperforming both RSNA CAD and Mirai. AI-based risk analysis supports ScreenPoint Medical’s commitment to women worldwide by powering personalized prevention pathways and enabling earlier diagnosis for less invasive treatment. Transpara Risk is approved for investigational use only.
In addition to Sunday’s session, the clinical and workflow benefits of Transpara Breast AI are the subject of notable presentations and posters throughout the week at RSNA:
The study, “Comparing Four Commercial AI Algorithms for Standalone Breast Cancer Detection on Digital Breast Tomosynthesis in a Dutch Population-based Screening Cohort” (T3-SSBR05-6, Tuesday, December 2, 9:30 AM, S406A) is the first study to compare commercial AI algorithms for screening DBT on the same large dataset. The results showed significant differences in performance between some of the four commercial AI algorithms with Transpara Detection outperforming the competition.
The poster, “Potential of Artificial Intelligence to Detect Interval Breast Cancers” (M5A-SPBR, Monday, December 1, 12:15 PM, Learning Center) suggests that Transpara Detection may have facilitated earlier detection of 38% of interval breast cancers, especially those missed or underestimated by radiologists. Research conducted at Johns Hopkins Medicine.
The study, “Use of Multiple Prior Exams Improves Specificity of an AI System for Breast Cancer Detection in a Retrospective Multi-site Validation” (T3-SSBR05, Tuesday, December 2, 9:30 AM, S406A) finds that Transpara Breast AI achieves a higher specificity when using prior exams for analysis.
The poster, “Real-World Performance of an FDA-approved Artificial Intelligence Tool for Screening Mammography” (W5B-SPBR-3, Wednesday, December 3, 12:45 PM, Learning Center) shows early positive results of clinical adoption into a busy screening mammography practice. Transpara Detection demonstrated strong performance in stratifying cancer risk and supporting recall decisions. Research conducted at Johns Hopkins Medicine.
The study, “AI Pre-reading of Digital Breast Tomosynthesis: A Multi-site Validation of a Novel Imaging Biomarker for Confident Identification of Normal DBT Examinations” (R1-SSBR10, Thursday, December 4, 8:00 AM, S406A), showed that a novel AI-driven imaging biomarker for pre-reading of DBT can confidently identify approximately one-third of normal DBT screening exams with a negative predictive value nearing 100%. This may enable pre-reading in screening, potentially allowing radiologists to accelerate the reading of this group of DBT exams, safely improving radiologist efficiency and reducing workload.
“We believe that research drives real-world results. The groundbreaking research presented at RSNA 2025 this week as well as our ongoing research across breast imaging RCTs support the reality that Transpara Breast AI is elevating the standard of care” said Pieter Kroese, CEO of ScreenPoint Medical. “Our partners, our performance, and our product are the reasons healthcare leaders consistently choose Transpara Breast AI. We look forward to fruitful dialogue and forward momentum at radiology’s leading conference.”
To discover more about the leading Breast AI solutions on the market, visit Booth #4719 (South Hall) at RSNA 2025 or schedule an online product overview after the show at https://screenpoint-medical.com
About ScreenPoint Medical
In the fight against breast cancer, every image is an opportunity: to unlock insight, to uncover risk, to embody health, to empower life. We build AI-powered technology for every step of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing patient experience, and translating opportunity into tangible outcomes.
Proven through research, driven by innovation, and tailor-made for those seeking to lead in breast health, ScreenPoint’s Transpara Breast AI is trusted by radiologists and women across the globe. We are Breast AI. Learn more at https://screenpoint-medical.com
PORT CANAVERAL, Fla., Nov. 30, 2025 /PRNewswire/ — Princess Cruises, one of the best-known names in cruising, today marked a major milestone with the arrival of the cruise line’s very first Royal-Class ship, Sky Princess, to homeport in Port Canaveral, beginning a season of Caribbean cruises from Central Florida.
Princess Cruises’ Sky Princess arrived at Cruise Terminal 6 this morning.
(Credit: Canaveral Port Authority)
Starting today and continuing through March 2026, Sky Princess will offer six- and eight-day Caribbean cruises to pristine beaches and tropical paradises, sailing roundtrip from Port Canaveral. The ship is scheduled to return next year for a second November 2026-March 2027 season – all cruises are on sale now.
Port Canaveral offers easy accessibility for guests driving, flying, or taking advantage of Princess’ exclusive Rail & Sail program with Brightline.
“Building on the success of our inaugural Caribbean season from Port Canaveral, we’re delighted to return to the Space Coast for another series of sailings,” said Jim Berra, Princess Cruises Chief Commercial Officer. “Our guests appreciate the convenience of cruising from Central Florida, and with the addition of Sky Princess, we’re pleased to offer even greater capacity and even more ways for guests to enjoy the Princess experience.”
Sky Princess itineraries can be combined into incredible 14-day voyages visiting the island paradises of Turks & Caicos, Puerto Rico, St. Thomas, Amber Cove, and much more.
“Princess Cruises is a valued partner and we’re very proud of the success they’ve had sailing from our Port,” said Port Canaveral CEO Capt. John Murray. “Sky Princess is a great addition to the lineup of cruise options from Central Florida. We look forward to delivering a high-quality guest experience for everyone sailing on this stunning new ship.”
The 3,660-guest, 141,000-ton Sky Princess elevates the distinctive, contemporary design and attractions of Princess’ renowned Royal-class ships. From award-winning cuisine and dynamic entertainment to elegantly appointed accommodations, Sky Princess delivers unforgettable experiences designed for today’s most discerning travelers.
Additional information about Princess Cruises is available through a professional travel advisor, by calling 1-800-PRINCESS (1-800-774-6237), or by visiting the company’s website at www.princess.com.
About Princess Cruises: Princess Cruises is The Love Boat, the world’s most iconic cruise brand that delivers dream vacations to millions of guests every year in the most sought-after destinations on the largest ships that offer elite service personalization and simplicity customary of small, yacht-class ships. Well-appointed staterooms, world class dining, grand performances, award-winning casinos and entertainment, luxurious spas, imaginative experiences and boundless activities blend with exclusive Princess MedallionClass service to create meaningful connections and unforgettable moments in the most incredible settings in the world – the Caribbean, Alaska, Panama Canal, Mexican Riviera, Europe, South America, Australia/New Zealand, the South Pacific, Hawaii, Asia, Canada/New England, Antarctica, and World Cruises. Star Princess, the brand’s newest and most innovative ship, launched October 2025, and sister ship to Sun Princess, named Condé Nast Traveler Mega Ship of the Year for a second consecutive year. The company is part of Carnival Corporation & plc (NYSE/LSE:CCL; NYSE:CUK).
SKYX Platforms has recently maintained its fair value estimate at $3.92 per share, reflecting stable expectations despite an evolving market landscape. The discount rate saw a slight decrease following a minor reduction in perceived risk. Revenue growth projections remain robust at 26.3% year-over-year. As developments continue, readers are encouraged to stay tuned for guidance on tracking future changes to the company’s narrative and valuation outlook.
Stay updated as the Fair Value for SKYX Platforms shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on SKYX Platforms.
Recent analyst coverage provides insight into prevailing sentiment among market watchers regarding SKYX Platforms. The latest report offers clear opinions on the company’s positioning and potential trajectory.
🐂 Bullish Takeaways
Litchfield Hills initiated coverage on SKYX Platforms with a Buy rating and set a $5 price target, signaling confidence in the company’s prospects.
The analyst highlighted the company’s plug-and-play SkyPlug ceiling and wall receptacle technology, which is approved in the National Electrical Code, as a key driver of potential growth.
Litchfield Hills compared SKYX Platforms’ business model to Qualcomm’s licensing strategy. This suggests significant long-term upside if the technology becomes a standard in the smart home sector.
The firm sees the technology’s potential as currently being undervalued by the market.
🐻 Bearish Takeaways
While overtly bearish commentary was not present in the latest research, Litchfield Hills did note the perception that the technology’s upside may not yet be fully recognized by investors. This implies some reservation about near-term realization of value.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NasdaqCM:SKYX Earnings & Revenue History as at Nov 2025
SKYX Platforms announced a partnership with Landmark Companies to supply over 15,000 smart plug and play units, including lighting and smart home products, for a new 340-unit residential development in San Antonio, Texas.
The company entered an agreement with Global Ventures Group to introduce its smart home solutions to residential, commercial, and hotel projects across the Middle East, particularly in Saudi Arabia and Egypt. This represents a significant step in expanding its international presence.
SKYX launched a new AI-driven software platform designed to increase website conversions and sales by 30 percent across 60 of its e-commerce websites focused on lighting, home decor, and smart technologies.
As part of its leadership transition plan, SKYX announced the retirement of Co-CEO John Campi. Leonard Sokolow will continue as Chief Executive Officer.
Fair Value: Remains stable at $3.92 per share, with no material change from previous assessments.
Discount Rate: Decreased slightly from 9.72% to 9.53%, reflecting a minor reduction in perceived risk.
Revenue Growth: No significant change. It holds steady at approximately 26.3% year-over-year.
Net Profit Margin: Essentially unchanged at around 1.21%, indicating consistent profitability expectations.
Future P/E: Declined marginally from 324.23x to 322.55x. This suggests a modest shift in forward earnings projections.
Narratives are a smarter, more accessible way to invest, connecting the story behind a company with its financial forecasts and fair value. On Simply Wall St’s Community page, millions of investors use Narratives to anticipate buy and sell moments by comparing Fair Value to the current market Price. Narratives update dynamically as news and earnings flow in, helping investors understand not just the numbers but also the reasons behind them.
Head over to the Simply Wall St Community Narrative on SKYX Platforms and stay updated on:
How broadening code approval and regulatory shifts could open up recurring, code-driven sales for SKYX Platforms, positioning it to set a new industry standard in smart home technology.
The impact of major partnerships, a growing patent portfolio, and stronger e-commerce execution on long-term adoption, margins, and market expansion.
Key risks and catalysts that could affect the company’s ability to scale, achieve consistent profitability, and capture future earnings, which can help you stay prepared as new information arrives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SKYX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Treatment with subcutaneous toripalimab (JS001sc) plus chemotherapy exhibited noninferior drug exposure compared with toripalimab injection (JS001) for the frontline treatment of patients with metastatic or recurrent nonsquamous non–small cell lung cancer (NSCLC) in the phase 3 JS001sc-002-III-NSCLC trial (NCT06505837), according to a news release from the drug’s developer, Junshi Biosciences.1
According to the developers, the intravenous agent displayed similar safety and efficacy compared to the subcutaneous indication, and the developers plan to present study data from the phase 3 trial at an upcoming international academic conference. Furthermore, they plan to submit a new drug application for JS001sc for all approved indications of JS001 to regulatory authorities.
“Since its launch as China’s first domestically developed PD-1 antibody drug, toripalimab has secured approvals for 12 indications, benefiting a significant number of patients. In clinical practice, we observed that patients undergoing immunotherapy, either as monotherapy or combination maintenance therapy, face challenges such as frequent intravenous catheterization and time-consuming infusions,” Jianjun Zou, MD, general manager and CEO of Junshi Biosciences, said in the news release.1 “The recent success of the phase 3 study for JS001sc, achieved through the efforts of both patients and the research team, marks not only a pivotal breakthrough in transitioning [immuno-oncology] therapy from efficacy to convenience but also exemplifies Junshi Biosciences’ patient-centric ambition.”
The study, led by Lin Wu, MD, from the Hunan Cancer Hospital in Changsha, China, sought to test the subcutaneous formulation of toripalimab and was the first phase 3 study to assess a domestic anti–PD-1 monoclonal antibody as a subcutaneous formulation. Most immunotherapy options are given intravenously in China. The developers express that this results in lengthy infusion times and inconveniences to patients.
The multicenter, open-label phase 3 trial randomly assigned patients with recurrent or metastatic nonsquamous NSCLC to receive subcutaneous toripalimab at 360 mg or intravenous toripalimab at 240 mg with chemotherapy.2 Patients in the subcutaneous arm received four 21-day cycles of JS001sc plus pemetrexed/platinum-containing chemotherapy and continued to receive JS001sc and pemetrexed as maintenance in the absence of disease progression for a maximum of 35 cycles. The same dosing regimen was followed in the intravenous arm.
The primary end points were observed serum trough concentration at cycle 1 and model-predicted area under the concentration-time curve. Secondary end points included objective response rate, progression-free survival, disease control rate, duration of response, and safety.
Those eligible for entry in the phase 3 study included patients 18 years or older with histologically or cytologically confirmed recurrent or metastatic nonsquamous NSCLC, a confirmation of an absence of EGFR-sensitive mutations or ALK fusions, and no prior systemic therapy for advanced or metastatic disease. Additionally, patients with 1 measurable lesion per RECIST v1.1 criteria, an ECOG performance score of 0 or 1, an expected survival of at least 12 weeks, and adequate organ function were included in trial enrollment.
Exclusion criteria included confirmation of concomitant disease states, including small cell lung cancer component, sarcomatoid lesion, or squamous cell carcinoma component greater than 10%; known meningeal metastases and symptomatic or asymptomatic brain metastases; uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; or spinal cord compression not treated surgically or radiotherapeutically. Furthermore, those with unresolved toxicities from previous antitumor therapies, known hypersensitivity to study agents, active case or history of autoimmune disease, and severe infection within 4 weeks of first use of study drug were also deemed ineligible for trial enrollment.
References
Junshi Biosciences announces primary endpoints met in JS001sc’s phase 3 study for the 1st-line treatment of NSQ-NSCLC. News release. Shanghai Junshi Biosciences. November 24, 2025. Accessed November 25, 2025. https://tinyurl.com/mwx5tefa
JS001sc or JS001 plus chemotherapy is indicated for relapsed or metastatic first-line non-squamous non small cell lung cancer (NSCLC). ClinicalTrials.gov. Updated August 28, 2025. Accessed November 25, 2025. https://tinyurl.com/25y8yytt
Oracle (ORCL) shares fell 28% in the past month as AI infrastructure fears triggered a 40% peak-to-trough correction.
Oracle holds a colossal cloud contract with OpenAI and stands to benefit directly from OpenAI’s growth.
Deutsche Bank highlights Oracle’s very real opportunity while acknowledging financial and operational risks from heavy debt.
Some investors get rich while others struggle because they never learned there are two completely different strategies to building wealth. Don’t make the same mistake, learn about both here.
It’s been yet another awful month for shares of the once-hyped AI infrastructure firm Oracle (NYSE:ORCL), which are down 28% in the past month after a peak-to-trough correction of 40%. With much of the latest AI dip arising from fears of what could go wrong if the heavier AI spenders don’t get the return they’re hoping for, it’s not a mystery to see Oracle stock leading the charge lower. A historic implosion followed a historic single-day surge. But such a quick correction shouldn’t come as a surprise, especially when you consider that volatility can hit both ways.
Though the future is cloudy for the aggressive AI infrastructure firm, I think it’s unfair to ditch the stock just because it’s leveraging up to seize a potential generational opportunity. If the AI boom really does lead to some form of superintelligence that sparks the rise of a digital labor force, and with that, a mass displacement of white-collar workers, the smartest move may very well be to be as aggressive as possible.
Of course, we’ll never really know if “flooring it” is the best possible move for Oracle until a few years down the road. If monetization never lives up to expectations, it could be quite the doozy for the firm as the weight of its debt becomes heavier. Just how likely is the bear case, though? It’s tough to say. I’d argue that a bull case might be likelier, especially if you’re in the belief that OpenAI is the horse to bet on in the AI model race.
Sure, overexposure to any single client may be a perceived negative by investors, but what if that one client ends up as the winning horse that passes the AGI (artificial general intelligence) finish line?
Though OpenAI has lost some of its luster in the past week, thanks in part to the impressive launch of the latest and greatest Google Gemini 3.0, one has to think that Sam Altman and company are hard at work readying to respond with a new model that’s just as big. With the GPT-5 fumble, I do think that OpenAI will take its time to ensure its next big launch is a hit.
Either way, the AI race is about to get more intense, and while Gemini may be pulling ahead in the model race, it’s a mistake to count out OpenAI and ChatGPT, especially since it’s hard to tell how the firm will respond. Leap-frogging in the AI race is quite common, and until OpenAI falls flat, I’m more inclined to think that more exposure to OpenAI might be a good thing, considering all the growth. Who knows? Perhaps Gemini and ChatGPT could both be winners when all is said and done, and the two AI innovators look to stay well ahead of their Chinese rivals.
With a colossal cloud contract with OpenAI, Oracle stands to benefit as Altman’s firm does. Of course, like Oracle, OpenAI has a significant amount of debt. And while all this debt can scare investors away from AI heavy hitters, I do think that the believers in the AI revolution might wish to spread their bets more broadly.
Even if you think Google and Gemini won’t give up their lead again, I think it’s also prudent to place bets on the firms tied to OpenAI’s fate as well, just in case the two AI leaders look to take different pathways. Either way, betting on the entire AI stack might be a good move, from the infrastructure layer (think Oracle) to model building, all the way up to the application layer.
With Deutsche Bank’s Brad Zelnick shining a light on the “very real opportunity” while also acknowledging “financial and operational risks” involved with the name, I’m inclined to view Oracle as a potentially big winner that investors might be severely discounting. The stakes may be high, but Oracle plays its cards right (and I think it has), the rewards might have the potential to be outsized.
In short, if there’s no AI bubble and OpenAI isn’t ready to wave the white flag after the Gemini 3.0 release (it most definitely won’t), Oracle may very well be on sale right now.
The fact is there are two totally different investment paths you can take right now. And while either can make you some money, choosing the right one at the right time can mean the difference between just getting by and getting truly rich. Most people don’t even realize the difference, and that mistake can be devastating for your portfolio. Whether you’re investing $1,000, or $1,000,000 today, learn the difference and put yourself on the right path. See the report.
Ford Motor stock is drawing renewed interest after its fair value estimate edged up from $12.27 to $12.52 per share, reflecting a slightly more optimistic outlook. This change comes as recent analyst commentary balances strong sales momentum and policy tailwinds with persistent challenges in the electric vehicle division and overall industry headwinds. Stay tuned to find out how you can stay informed about ongoing updates to Ford’s evolving market narrative.
Stay updated as the Fair Value for Ford Motor shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ford Motor.
Recent analyst commentary on Ford Motor reveals a mix of optimism and caution, with several major firms updating their outlooks following third quarter results, industry developments, and changes in policy and electric vehicle (EV) performance.
🐂 Bullish Takeaways
JPMorgan, maintaining an Overweight rating, raised its price target for Ford from $13 to $14. The firm cites stronger global light vehicle production and positive trends in currencies and commodities. While JPMorgan prefers auto suppliers overall, it still sees Ford benefiting from industry momentum.
Goldman Sachs increased its price target from $11 to $12 after raising its U.S. auto sales forecast, highlighting solid year-to-date sales and “relatively benign” industry pricing strategies. The analyst notes that demand indicators are supporting a better outlook for volume.
Jefferies upgraded Ford from Underperform to Hold, raising its price target to $12 from $9. The firm pointed to Ford’s strong mix of large vehicles positioned to offset tariffs and improve profitability, while affirming Ford’s commitment to electrification and the potential to benefit from policy adjustments.
BofA, while lowering its price target slightly to $13.50 from $14, remains above consensus on near-term operating performance. The firm expects a Q3 EBIT above consensus and notes higher consensus estimates since Q2 earnings.
RBC Capital lifted its price target to $12 from $11, recognizing strong Q3 results that benefited from pull-forward effects. The analyst expects recent tariff adjustments and fire recovery efforts to support upward revisions to estimates.
🐻 Bearish Takeaways
Wells Fargo remains cautious, raising its price target to $10 from $8 but maintaining an Underweight rating. The analyst highlights concerns over D3 pricing, volume balance, and rising warranty costs as well as potential profit-taking if expectations are not exceeded.
BofA, despite a generally positive stance, revised down its 2026 estimates due to slower margin improvement at Ford Pro and higher-than-expected losses at Ford Model e, reflecting ongoing challenges in Ford’s EV segment.
Jefferies, despite the upgrade, describes Ford shares as “relatively expensive” at current levels and warns that valuation could limit further upside in the near term.
Overall, while the analyst community recognizes Ford Motor’s solid execution and strategic positioning, especially among its full-size vehicle lineup and through select partnerships, valuation concerns and persistent challenges in the electric vehicle business continue to temper broader bullish enthusiasm.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NYSE:F Community Fair Values as at Nov 2025
The Senate Committee will question Detroit automakers, including Ford, at a January hearing focused on the rising cost of vehicles and the effectiveness of auto-safety mandates.
Novelis, Ford’s primary aluminum supplier, has experienced a third major fire in two months. This has led to potential earnings losses for Ford and production cuts in several popular models.
Executives at Ford are weighing whether to discontinue the electric F-150 Lightning due to weaker-than-expected sales. This could make it the first significant electric vehicle model to be shuttered by a major U.S. automaker.
Ford has announced a $370 million investment to restart a manufacturing facility in India, focusing on new engine production for export markets outside the United States.
The Fair Value Estimate has increased slightly from $12.27 to $12.52 per share.
The Discount Rate remains unchanged at 12.5%.
The Revenue Growth projection has improved modestly, moving from -1.21% to -1.15% year-over-year.
The Net Profit Margin forecast is up marginally, from 3.52% to 3.53%.
The Future P/E Ratio has increased moderately, rising from 10.90x to 11.16x.
A Narrative is your story behind the numbers. It connects your perspective on a company’s future (like Ford’s fair value, revenue, earnings, and margins) to real financial forecasts. Narratives link these forecasts to a fair value, making them a simple, accessible tool on Simply Wall St’s Community page. Millions of investors use Narratives to compare fair value to price, helping them decide when to buy or sell. Best of all, Narratives are always kept current as news and results come in.
Interested in what’s next for Ford? Read the full original Narrative for in-depth insights and dynamic updates, and stay ahead as Ford’s story evolves.
Track the impact of Ford’s shift toward digital services, cost savings, and realigned EV strategy on long-term profitability.
Follow ongoing risks, including tariff headwinds and challenges from Ford’s heavy reliance on legacy vehicles and ICE models.
See how changes in regulations, market trends, and new manufacturing initiatives shape the fair value and future outlook for Ford Motor.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include F.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
